Humana (HUM) Fundamentals 2026 — P/E 42.3x, Revenue Analysis | SniperIQ
Humana (HUM) is a US-listed Healthcare company in Medical - Healthcare Plans with a market capitalization of $47.7B, trading at
Humana (HUM) is a US-listed Healthcare company in Medical - Healthcare Plans with a market capitalization of $47.7B, trading at
Humana (HUM) has a market capitalization of approximately $47.7B, trading at
Humana's trailing twelve-month P/E ratio is 42.3x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Humana runs a net profit margin of 0.8%, a gross margin of 14.0%, and an operating margin of 1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Humana reported revenue of
Humana offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Humana carries a debt-to-equity ratio of 0.75x and a current ratio of 1.26x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Humana (HUM) the key facts are: market cap $47.7B, P/E 42.3x, revenue
Get Humana's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.